Published on 6 Oct 2024 on GuruFocus.com · via Yahoo Finance
ADMA Biologics Inc (ADMA) Q2 2024 Earnings Call Highlights: Record Revenue and...
Total Revenue: $107.2 million for Q2 2024, a 78% increase year-over-year.Adjusted EBITDA: $44.5 million, nearly 600% growth year-over-year.GAAP Net Income: $32.1 million, compared to a GAAP net loss of $6.4 million in Q2 2023.Gross Profit: $57.5 million, a 244% increase from Q2 2023.Gross Margin: 53.6% in Q2 2024, up from 27.8% in Q2 2023.Free Cash Flow: $43.4 million generated in Q2 2024.ASCENIV Revenue Contribution: Surpassed 50% of total revenue.Revenue Guidance 2024: Expected to exceed $400 million.Revenue Guidance 2025: Expected to exceed $445 million.Adjusted EBITDA Guidance 2024: Expected to exceed $150 million.Adjusted EBITDA Guidance 2025: Expected to exceed $200 million.Net Income Guidance 2024: Expected to exceed $105 million.Net Income Guidance 2025: Expected to exceed $155 million.
Warning! GuruFocus has detected 6 Warning Sign with ADMA.